Abstract
Background Enteric infections are important causes of morbidity and mortality, yet clinical surveillance is limited. Wastewater-based epidemiology (WBE) has been used to study community circulation of individual enteric viruses and panels of respiratory diseases, but there is limited work studying concurrent circulation of a suite of important enteric viruses.
Methods A retrospective WBE study was carried out at two wastewater treatment plants located in California, United States. Using droplet digital polymerase chain reaction (PCR), we measured concentrations of human adenovirus group F, enteroviruses, norovirus genogroups I and II, and rotavirus nucleic-acids in wastewater solids two times per week for 26 months (n=459 samples) between 2/1/21 and 4/14/23. A novel probe-based PCR assay was developed and validated for adenovirus. We compared viral nucleic-acid concentrations to positivity rates for viral infections from clinical specimens submitted to a local clinical laboratory to assess concordance between the data sets.
Findings We detected all viral targets in wastewater solids. At both wastewater treatment plants, human adenovirus group F and norovirus GII nucleic-acids were detected at the highest concentrations (median concentrations greater than 105 cp/g), while rotavirus RNA was detected at the lowest concentrations (median on the order of 103 cp/g). Rotavirus, adenovirus group F, and norovirus nucleic-acid concentrations were positivity associated with clinical specimen positivity rates. Concentrations of tested viral nucleic-acids exhibited complex associations with SARS-CoV-2 and other respiratory viral nucleic-acids in wastewater, suggesting divergent transmission patterns.
Interpretation This study provides evidence for the use of wastewater solids for the sensitive detection of enteric virus targets in WBE programs aimed to better understand the spread of enteric disease at a localized, community level without limitations associated with testing many individuals. Wastewater data can inform clinical, public health, and individual decision making aimed to reduce transmission of enteric disease.
Competing Interest Statement
BH, DD, and BW are employees of Verily Life Sciences, LLC.
Funding Statement
This work was funded by a gift from the Sergey Brin Family Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed by the Stanford University Institutional Review Board (IRB) and the IRB determined that this research does not involve human subjects and is exempt from oversight.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Wastewater data are available publicly at the Stanford Digital Repository (https://doi.org/10.25740/vx726fw9373). Positivity rate data for clinical specimens are available upon request.
